Skip to main content
. 2014 May 16;28(7):895–899. doi: 10.1038/eye.2014.101

Figure 2.

Figure 2

A patient with persistent SRF despite 22 prior anti-VEGF injections (1 Bevacizumab and 21 Ranibizumab) over the prior 22 months and was transitioned to aflibercept. Following 12 monthly aflibercept injections, SRF substantially reduced on SD-OCT. CFT improved from 341 to 319 μm and macular volume reduced from 10.01 to 9.34 mm3. Visual acuity was preserved at 20/60.